针对抗血管生成药物的药物不良反应机制及处理研究进展

中国综合临床 Pub Date : 2019-09-01 DOI:10.3760/CMA.J.ISSN.1008-6315.2019.05.022

Jianfang Shao, Bin Dong, Qinghua Zhang

{"title":"针对抗血管生成药物的药物不良反应机制及处理研究进展","authors":"Jianfang Shao, Bin Dong, Qinghua Zhang","doi":"10.3760/CMA.J.ISSN.1008-6315.2019.05.022","DOIUrl":null,"url":null,"abstract":"Angiogenesis plays an important role in the occurrence, development and metastasis of malignant tumors, and anti-angiogenesis has become an important therapeutic method in molecular targeted therapy of tumors.At present, the commonly used anti-angiogenesis drugs include monoclonal antibodies (bevacizumab), tyrosine kinase inhibitors (sorafenib, sunitinib), and endothelial cell growth inhibitors.The adverse reactions of different kinds of targeted anti-angiogenesis drugs are different.To grasp the mechanism of adverse reactions and the treatment measures of related adverse reactions of these drugs will improve the tolerance of patients receiving this kind of drugs, and at the same time, the prognosis of patients will be further improved. \n \n \nKey words: \nTargeted therapy of tumor; Anti-angiogenie drugs; Adverse reactions","PeriodicalId":10365,"journal":{"name":"中国综合临床","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2019-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Advances in mechanism and management of adverse drug reactions targeting anti-angiogenesis drugs\",\"authors\":\"Jianfang Shao, Bin Dong, Qinghua Zhang\",\"doi\":\"10.3760/CMA.J.ISSN.1008-6315.2019.05.022\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Angiogenesis plays an important role in the occurrence, development and metastasis of malignant tumors, and anti-angiogenesis has become an important therapeutic method in molecular targeted therapy of tumors.At present, the commonly used anti-angiogenesis drugs include monoclonal antibodies (bevacizumab), tyrosine kinase inhibitors (sorafenib, sunitinib), and endothelial cell growth inhibitors.The adverse reactions of different kinds of targeted anti-angiogenesis drugs are different.To grasp the mechanism of adverse reactions and the treatment measures of related adverse reactions of these drugs will improve the tolerance of patients receiving this kind of drugs, and at the same time, the prognosis of patients will be further improved. \\n \\n \\nKey words: \\nTargeted therapy of tumor; Anti-angiogenie drugs; Adverse reactions\",\"PeriodicalId\":10365,\"journal\":{\"name\":\"中国综合临床\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"中国综合临床\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3760/CMA.J.ISSN.1008-6315.2019.05.022\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"中国综合临床","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1008-6315.2019.05.022","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

血管生成在恶性肿瘤的发生、发展和转移中起着重要作用，抗血管生成已成为肿瘤分子靶向治疗的重要治疗手段。目前常用的抗血管生成药物包括单克隆抗体(贝伐单抗)、酪氨酸激酶抑制剂(索拉非尼、舒尼替尼)和内皮细胞生长抑制剂。不同类型的靶向抗血管生成药物的不良反应不同。掌握这些药物不良反应的发生机制及相关不良反应的治疗措施，将提高患者对该类药物的耐受性，同时进一步改善患者的预后。关键词:肿瘤靶向治疗;Anti-angiogenie药物;不良反应

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Advances in mechanism and management of adverse drug reactions targeting anti-angiogenesis drugs

Angiogenesis plays an important role in the occurrence, development and metastasis of malignant tumors, and anti-angiogenesis has become an important therapeutic method in molecular targeted therapy of tumors.At present, the commonly used anti-angiogenesis drugs include monoclonal antibodies (bevacizumab), tyrosine kinase inhibitors (sorafenib, sunitinib), and endothelial cell growth inhibitors.The adverse reactions of different kinds of targeted anti-angiogenesis drugs are different.To grasp the mechanism of adverse reactions and the treatment measures of related adverse reactions of these drugs will improve the tolerance of patients receiving this kind of drugs, and at the same time, the prognosis of patients will be further improved. Key words: Targeted therapy of tumor; Anti-angiogenie drugs; Adverse reactions

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

中国综合临床

CiteScore

0.10

自引率

0.00%

发文量

16855

期刊介绍： Clinical Medicine of China is an academic journal organized by the Chinese Medical Association (CMA), which mainly publishes original research papers, reviews and commentaries in the field. Clinical Medicine of China is a source journal of Peking University (2000 and 2004 editions), a core journal of Chinese science and technology, an academic journal of RCCSE China Core (Extended Edition), and has been published in Chemical Abstracts of the United States (CA), Abstracts Journal of Russia (AJ), Chinese Core Journals (Selection) Database, Chinese Science and Technology Materials Directory, Wanfang Database, China Academic Journal Database, JST Japan Science and Technology Agency Database (Japanese) (2018) and other databases.